The CPS, which quantifies PD-L1 expression in macrophages and lymphocytes in relation to the total tumor cell numbers, guides clinicians regarding treatment options for diseases such as HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.